News
Events
SciBase partner with a large health care group in Los Angeles, Unified Health, and receives a first order
June 28, 2024STOCKHOLM, SVERIGE, 28 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase], a leading developer of augmented intelligence-based solutions for skin disorders announced today that it continues to expand in California with a collaboration agreement with Unified Health. Unified Health has nine clinics in Southern California.
SciBase welcomes new chairman and thanks the former
June 13, 2024STOCKHOLM, SVERIGE, 13 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase, a leading developer of AI-based solutions for skin diseases, today announces the election of Jesper Høiland as the new Chairman of the Board.
SciBase strengthens the US organization with experienced leader in dermatology
STOCKHOLM, SVERIGE, 13 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase, a leading developer of AI-based solutions for skin diseases, today announces that Leda Beaty has been appointed Head of US Commercial Operations.
Today is the first day of trading in the new shares and warrants of series TO 2 issued in connection with the completed capital raising
May 31, 2024Today, 31 May 2024, trading in the new shares and warrants of series TO 2 begins, which were issued by SciBase Holding AB (publ) ("SciBase" or the "Company") in connection with the capital raising announced by the Company on 5 April 2024, consisting of a rights issue of units of up to approximately SEK 15 million (the "Rights Issue") and a directed issue of units of approximately SEK 33 million (the "Directed Issue" and together with the Rights Issue the "Capital Raising"). The Rights Issue was resolved by the Board of Directors in SciBase on 5 April 2024, pursuant to the authorisation granted by the Annual General Meeting held on 17 May 2023, and the Directed Issue was resolved by the Board of Directors on 5 April 2024, conditional on the subsequent approval by the general meeting. The extraordinary general meeting in the Company on 13 May 2024 resolved to approve the Board of Directors resolution to carry out the Directed Issue.
SciBase receives first order in Austria
May 30, 2024STOCKHOLM, SWEDEN, - May 30, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of artificial intelligence (AI)-based solutions for skin disorders is pleased to announce that it has received the first order for a Nevisense system with electrodes in Austria.
SciBase Announces the launch of eBarrier Score, the First AI-Driven Skin Barrier Assessment tool for research and Cosmetic Testing
May 29, 2024STOCKHOLM, SWEDEN, - May 29, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of artificial intelligence (AI)-based solutions for skin disorders is pleased to announce the launch of the eBarrier Score for Nevisense, the first-ever AI skin barrier assessment tool built for use in research and cosmetic testing. The eBarrier Score was announced today at the Cosmetotest cosmetic testing symposium in Lyon, France.
New German study shows Nevisense significantly improves dermatologists clinical decisions
May 22, 2024STOCKHOLM, SWEDEN, - May 22, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that a new clinical study has been published presenting the improvement that the Nevisense provides over visual and dermoscopic evaluation when clinical evaluations were done by German dermatologists. The article named "Utilizing Data from Electrical Impedance Spectroscopy Significantly Improves the Decision to Biopsy Pigmented Skin Lesions Beyond Clinical Evaluation and Dermoscopy" has been published in the journal "SKIN - The journal of cutaneous medicine". The study included 151 German Dermatologists making a total of 22.197 clinical biopsy decisions. Nevisense was able to improve the rate of correct biopsy choice even after dermoscopic evaluation. While dermoscopy worsened diagnostic accuracy for benign lesions, Nevisense results were able to significantly improve decision making for these lesions as well. This study demonstrates the clinical utility of Nevisense technology for improving melanoma diagnosis.
SciBase publishes the Annual report for 2023
SciBase hereby announces that the Annual report for 2023 is available at the Company's website www.scibase.com.
SciBase announces outcome in the directed issue of units
May 13, 2024On 5 April 2024 SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's board of directors resolved, subject to subsequent approval by the general meeting, on directed issues of a total of 77,891,769 units consisting of shares and warrants of series TO 2, with deviation from the shareholders preferential rights, to a total approximate amount of SEK 33 million (the "Directed Issue"). The subscription price in the Directed Issue amounted to SEK 0.42 per unit, corresponding to SEK 0.42 per share. The extraordinary general meeting on 13 May 2024 resolved to approve the Directed Issue. All units in the Directed Issue have been subscribed and the board of directors has therefore today, on 13 May 2024, resolved on allotment of all units in the Directed Issue.
Bulletin from the extraordinary general meeting in SciBase Holding AB (publ)
Today, an extraordinary general meeting has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance with the proposals presented in the notice to attend the meeting (which is available on the Company's website (www.scibase.com)):
SciBase announces outcome in rights issue of units
May 10, 2024The Board of Directors in SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome in the rights issue of so called units, consisting of shares and warrants of series TO 2 ("Units"), with preferential rights for the Company's existing shareholders of approximately SEK 15 million which was resolved upon by the Board of Directors on 5 April 2024 by virtue of the authorization from the annual general meeting on 17 May 2023 (the "Rights Issue"). The subscription price in the Rights Issue was SEK 0.42 per Unit, corresponding to SEK 0.42 per share. The warrants of series TO 2 are issued free of charge. The subscription period in the Rights Issue ended on 7 May 2024. 13,264,074 Units were subscribed for with support of unit rights, corresponding to approximately 37 percent of the Rights Issue. 8,493,194 Units, corresponding to approximately 24 percent of the Rights Issue, have been allotted to persons who have subscribed for Units without support of unit rights. In total, 21,757,268 Units were subscribed for in the Rights Issue, corresponding to approximately 61 percent of the Rights Issue. Through the Rights Issue, the Company will initially receive proceeds of approximately SEK 9 million before deduction of transaction costs. If all warrants of series TO 2 issued in the Rights Issue are exercised for subscription of shares the Company will receive additional proceeds of approximately SEK 46 million before deduction of transaction costs.
Last day of trading in unit rights in SciBase rights issue
May 2, 2024Today, 2 May 2024, is the last day of trading in unit rights in SciBase Holding AB (publ) ("SciBase" or the "Company") rights issue of units of up to approximately SEK 15 million (the "Rights Issue"). The Rights Issue was resolved by the Board of Directors in SciBase on 5 April 2024, pursuant to the authorisation granted by the Annual General Meeting held on 17 May 2023.
- Load more news...